Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

被引：12

作者：

DiNardo, Courtney D. ^{[1
]}

Watts, Justin M. ^{[2
]}

Stein, Eytan M. ^{[3
]}

De Botton, Stephane ^{[4
]}

Fathi, Amir T. ^{[5
]}

Prince, Gabrielle T. ^{[6
]}

Stein, Anthony S. ^{[7
]}

Foran, James M. ^{[8
]}

Stone, Richard M. ^{[9
]}

Patel, Prapti A. ^{[10
]}

Tallman, Martin S. ^{[3
]}

Choe, Sung ^{[11
]}

Wang, Hongfang ^{[11
]}

Zhang, Vickie ^{[11
]}

Dai, David ^{[11
]}

Fan, Bin ^{[11
]}

Yen, Katharine E. ^{[11
]}

Kapsalis, Stephanie M. ^{[11
]}

Hickman, Denice ^{[11
]}

Agresta, Samuel V. ^{[11
]}

Liu, Hua ^{[11
]}

Wu, Bin ^{[11
]}

Attar, Eyal C. ^{[11
]}

Kantarjian, Hagop M. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Inst Gustave Roussy, Villejuif, France

[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[6] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA

[7] City Hope Med Ctr, Duarte, CA USA

[8] Mayo Clin, Jacksonville, FL 32224 USA

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Univ Texas Southwestern Med Ctr, Dallas, TX USA

[11] Agios Pharmaceut Inc, Cambridge, MA USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-111264

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1812

引用

页数：3

共 50 条

[31] Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study.
Dai, David
Dinardo, Courtney Denton
Stein, Eytan
de Botton, Stephane
Attar, Eyal C.
Liu, Hua
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[32] AG-120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION
Mellinghoff, Ingo K.
Touat, Mehdi
Maher, Elizabeth
De la Fuente, Macarena
Cloughesy, Timothy F.
Holdhoff, Matthias
Cote, Gregory M.
Burris, Howard
Janku, Filip
Huang, Ray
Young, Robert J.
Ellingson, Benjamin
Nimkar, Tara
Jiang, Liewen
Ishii, Yuko
Choe, Sung
Fan, Bin
Steelman, Lori
Yen, Katharine
Bowden, Chris
Pandya, Susan
Wen, Patrick Y.
NEURO-ONCOLOGY, 2017, 19 : 10 - 11
[33] AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS
Mellinghoff, Ingo K.
Touat, Mehdi
Maher, Elizabeth
DeLaFuente, Macarena
Cloughesy, Timothy F.
Holdhoff, Matthias
Cote, Gregory
Burris, Howard
Janku, Filip
Huang, Raymond
Young, Robert
Ellingson, Benjamin
Auer, Julia
Liu, Hua
Hurov, Jonathan
Yen, Katherine
Agresta, Sam
Attar, Eyal
Pandya, Susan
Wen, Patrick Y.
NEURO-ONCOLOGY, 2016, 18 : 12 - 12
[34] A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.
Mellinghoff, Ingo K.
Cloughesy, Timothy Francis
Wen, Patrick Y.
Taylor, Jennie Webster
Maher, Elizabeth A.
Arrillaga, Isabel
Peters, Katherine B.
Choi, Changho
Ellingson, Benjamin M.
Lin, Alexander P.
Thakur, Sunitha B.
Nicolay, Brandon
Lu, Min
Le, Kha
Yin, Feng
Tai, Feng
Schoenfeld, Steven
Steelman, Lori
Pandya, Shuchi Sumant
Clarke, Jennifer Leigh
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study
DiNardo, Courtney
de Botton, Stephane
Pollyea, Daniel A.
Stein, Eytan M.
Fathi, Amir T.
Roboz, Gail J.
Collins, Robert
Swords, Ronan T.
Flinn, Ian W.
Altman, Jessica K.
Tallman, Martin S.
Kantarjian, Hagop M.
Derti, Adnan
Goldwasser, Meredith
Prahl, Malia
Wu, Bin
Yen, Katherine
Agresta, Sam
Stone, Richard M.
BLOOD, 2015, 126 (23)
[36] Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.
Stein, Eytan M.
Dinardo, Courtney Denton
Pollyea, Daniel Aaron
Fathi, Amir Tahmasb
Roboz, Gail J.
Altman, Jessica K.
Stone, Richard M.
Flinn, Ian
Kantarjian, Hagop M.
Collins, Robert
Patel, Manish R.
Stein, Anthony Selwyn
Sekeres, Mikkael A.
Swords, Ronan T.
Medeiros, Bruno C.
Knight, Robert D.
Agresta, Samuel V.
De Botton, Stephane
Tallman, Martin S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[37] ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study
Shah, Jatin J.
Zonder, Jeffrey
Cohen, Adam
Orlowski, Robert Z.
Alexanian, Raymond
Thomas, Sheeba K.
Weber, Donna
Kaufman, Jonathan L.
Harvey, R. Donald
Walker, Duncan
Litwiler, Kevin
Karan, Sharon
Hilder, Brandi
Ptaszynski, Ann Marie
Lonial, Sagar
BLOOD, 2011, 118 (21) : 809 - 810
[38] TQB3454 in mutant IDH1 advanced cholangiocarcinoma (CCA): Results of a phase I dose escalation and expansion study cohort
Yuan, J.
Zheng, Y.
Xu, L.
Xie, F.
Gu, S.
Li, Q.
Zhang, J.
Ba, Y.
Huaxin, D.
Yang, A.
Li, J.
Zhou, J.
Shen, L.
ANNALS OF ONCOLOGY, 2024, 35 : S120 - S120
[39] A first-in-human, phase 1, dose escalation study of SGR-2921 as monotherapy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
Weiss, Daniel
Dinardo, Courtney Denton
Strickland, Stephen Anthony
Skikne, Barry
Zeidan, Amer Methqal
Traer, Elie A.
Carraway, Hetty E.
Carraway, Hetty E.
Frankel, Stanley R.
Wang, Jacky
Pirie-Shepherd, Steven Robert
Piccotti, Joseph R.
Wright, Duncan Hamish
Akinsanya, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[40] Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Hamadani, Mehdi
Collins, Graham P.
Caimi, Paolo F.
Samaniego, Felipe
Spira, Alexander
Davies, Andrew
Radford, John
Menne, Tobias
Karnad, Anand
Zain, Jasmine M.
Fields, Paul
Havenith, Karin
Cruz, Hans G.
He, Shui
Boni, Joseph
Feingold, Jay
Wuerthner, Jens
Horwitz, Steven
LANCET HAEMATOLOGY, 2021, 8 (06): : E433 - E445

← 1 2 3 4 5 →